Celularity Inc

Celularity Inc. (Nasdaq: GXGX) is a clinical-stage cell therapy company that entered the public markets through a business combination with GX Acquisition Corp. II, a blank-check vehicle sponsored by GX Sponsor II LLC, an affiliate of GX Clarke Capital Holdings. The SPAC completed its initial public offering in 2021, targeting the biotechnology and life sciences sector. Celularity focuses on developing allogeneic, off-the-shelf cellular therapeutics sourced from the human placenta. The company filed an 8-K current report with the Securities and Exchange Commission on August 7, 2026. For complete filing history, sponsor intelligence, and deal analytics on Celularity and thousands of other SPAC transactions, sign up for full data access at SpacDesk.